Lähettäjä: Soijuv Lähetetty: 24.7.2007 7:05
Lääkkeitä ei ilmeisesti vieläkään syödä eikä voittoa saada riittävästi sillä seuraavan artikkelin mukaan "Amerikan lääkelaitos yrittää nyt vähentää markkinoilta useita lisäravinteita valmistavia yrityksiä jotta saisi tätä kautta valmisteiden hinnat nousemaan ja ihmiset lopettamaan niiden käytön. Toimenpiteen päämääränä on jättää lääketeollisuuden kemialliset lääkkeet kuluttajien ainoaksi vaihtoehdoksi hoitaa itseään."
FDA ANNOUNCES PLAN TO ELIMINATE VITAMIN COMPANIES
By Byron J. Richards, CCN
June 27, 2007
NewsWithViews.com
The FDA, emboldened by its transformation into a drug company, has embarked upon an anti-American plan of interfering with business and intentionally eliminating various dietary supplement companies from the market. The FDA announcement came on Friday, June 22, 2007 under the guise of a final rule for dietary supplement good manufacturing practices (CGMPs). Within this 800 page rule the FDA states, ?We find that this final rule will have a significant economic impact on a substantial number of small entities.... Establishments with above average costs, and even establishments with average costs, could be hard pressed to continue to operate. Some of these may decide it is too costly and either change product lines or go out of business.... 140 very small [less than 20 employees] and 32 small dietary supplement manufacturers [less than 500 employees] will be at risk of going out of business.... costs per establishment are proportionally higher for very small than for large establishments.... The regulatory costs of this final rule will also discourage new small businesses from entering the industry.?
This FDA rule will directly raise the price of dietary supplements for all consumers. The FDA acknowledges this and says ?We expect that the majority of these costs will be borne by consumers of dietary supplements, who will likely respond to the increase in prices by reducing consumption.? Thus, the FDA is intentionally seeking to shrink the size of the dietary supplement industry and reduce the influence of safe and effective options to improve the dreadful trend in the health of Americans. The goal is to leave toxic drugs as the primary health option.
Independent analysis of this FDA rule has placed cost of compliance at 10 fold what the FDA estimates with as many as 50% of small companies unable to comply.
The gutless cowards of Congress, a majority of whom are on the Big Pharma payroll or will be on it once they leave Congress, have delegated their lawmaking powers granted by the U.S. Constitution to a bunch of Big Pharma-friendly unelected bureaucrats at the FDA, who are in turn using this power to undermine free commerce and help Big Pharma eliminate competition from the market. This is the behavior of a government in tyranny, inviting a revolution by the people. It is noteworthy that fascist governments of the past have eliminated health freedom and health options as a necessary condition to enslave and brainwash a population. Congress has delegated its responsibility to the people to such an extent that over half the laws in this country are now concocted by unelected bureaucrats with vested interests.
A Vehicle for Unprecedented Harassment
Any company that can afford to comply with the costs and regulations of this new FDA rule can be targeted and eliminated at will by the FDA. In essence, the FDA is seeking to make the dietary supplement industry document every phase of production, including expensive testing at multiple points in the production process. Massive recordkeeping will be required, including all customer complaints and returns for any reason! This is utterly draconian and unnecessary interference and burden to free commerce. It is completely Anti-American. No doubt, the FDA will impose user fees as an additional charge so that FDA agents will have the funding required to enforce the regulations. Under the new rule any flaw in bookkeeping can result in a company?s products being declared adulterated, allowing the FDA to remove them from the market even though nothing is wrong with them! A company can then be forced out of business because they won?t be able to sell any products to raise the money to comply. The rules are so complex and vague that the FDA can selectively target any company it chooses, even those attempting to comply in good faith.
The FDA is doing this under the pretense of improved consumer safety. Consumer safety could readily be guaranteed by simply having all companies test their final products for purity and potency. Instead of this simple approach the FDA has gone to the extreme of burdening the dietary supplement industry with regulations in excess of the drug industry! Supplements are foods, not drugs. The food industry couldn?t begin to comply with these FDA rules, even though food contamination is far more dangerous to health than dietary supplements.
The FDA intends to phase this rule in over the next three years. This means that within five years half the industry and many of the health options individuals rely on will either be gone or significantly more expensive.
Even more chilling is that forces within the dietary supplement industry itself are in no small part responsible for this FDA final rule.
Trade Groups and their Big Companies Turn on America
The Natural Products Association (formerly the National Nutritional Food Association ? NNFA) and the Council for Responsible Nutrition (CRN) have been instrumental in forcing these drug-like rules on dietary supplements. These globalist organizations are selling out America, destroying American jobs, undermining the U.S. Constitution, and working in conjunction with pharmaceutical companies to usher in Codex and the New World Order. Consumers of dietary supplements should learn who these companies are before buying their products and helping to inadvertently fund the destruction of health freedom in this country.
When DSHEA was passed in 1994 part of that law required the FDA to establish current good manufacturing practices (CGMPs) for the dietary supplement industry. During a period of FDA outreach to the industry the FDA was surprised to learn that CRN and NPA were in favor of drug-like CGMPs for the dietary supplement industry. These trade groups, working closely with Senators Orin Hatch (R-UT) and Tom Harkin (D-IA), have intentionally taken the supplement industry down a slippery slope. It is noteworthy that Hatch takes in more money from Big Pharma than he does from dietary supplement companies. Not only is Hatch a big supporter of the Medicare Part D drug rip off of Americans he has saved Big Pharma billions by protecting them from generic competition, as he is currently attempting to do with his legislation for new biologic drugs. Hatch also has a son working for NPA and another son that lobbies for NPA and the dietary supplement industry. When Hatch leaves the Senate he will be first in line for a six or seven figure Big Pharma salary.
The CRN has been taken over by multinational drug and food companies. Key players are the nutritional divisions of Bayer, BASF, Cargill, Monsanto, Wyeth, and Archer Daniels Midland. Nutrition companies that participate are in most cases owned by pharmaceutical companies, heavily invested in pharmaceutical companies, or jockeying for position in the international market as part of the New World Order. Key names include Mannatech, Shaklee, Herbalife, GNLD International, The Vitamin Shoppe, and GNC. These companies are glad to eliminate competition from small companies and start up ventures.
Carrying on the general theme of Big Pharma ownership and a globalist agenda are the companies that control the NPA. One need only look at the new NPA China board to understand who these key players are. Jarrow Formulas, Now Foods, GNC, and Herbalife top the list. At the end of 2006 Jarrow and Now helped lead the charge with Senators Hatch and Harkin to burden the dietary supplement industry with bizarre Adverse Event Reporting legislation (AER) which insisted that dietary supplement companies keep extensive records on any type of consumer complaint. Aspects of this AER law are now implemented in the FDA final rule on CGMPs. Of course, NPA was quick to offer expensive training to its members to indoctrinate them into how to comply with the rules that NPA, working on behalf of the FDA, just forced on its own members. Are their member companies really this stupid? Or are they all working together? I would recommend that any NPA member that believes itself to be a true American company that values our constitution immediately withdraw from NPA membership ? consumers will be looking to see who you are.
The picture is now crystal clear for any person who cares to look.
Numerous dietary supplement companies are anti-American and actively selling out our country and our constitution, working hand-in-glove with the FDA and Big Pharma. The majority of such companies can be found as members of CRN and NPA. It will be up to the American consumer to save the dietary industry from itself and preserve their own access to safe and effective natural health remedies. This is a relatively simple task. Quit buying products from or quit being a distributor in these fascist organizations. Support the small companies that are the backbone of America, otherwise they will soon be extinct.
Update on S.1082 Threat to Dietary Supplements
Many of you have been following the extreme threat to dietary supplements posed by S.1082. Similar legislation has now cleared the House Energy and Commerce Committee and is headed for the floor of the House in the next week or two. The House version of this bill now contains the ?food and food ingredients? language that the FDA can use to apply drug-related risk/benefit analysis to dietary supplements and have them removed from the market at their whim.
It is noteworthy that both CRN and NPA have posted on their websites information stating that S.1082 is not a threat to dietary supplements. Both organizations are flat out wrong. They cite a colloquy by Hatch, Harkin, Kennedy, and Enzi as their evidence. This colloquy was a direct result of our grassroots campaign to alert the American consumer to this major threat. In no way does this colloquy protect dietary supplements. UNTIL THE LANGUAGE IN THE BILL IS CHANGED THE THREAT EXISTS AND IS VERY REAL
LÄÄKETEOLLISUUDEN KEINOJA KASVATTAA LÄÄKKEIDEN KULUTUSTA
Valvojat: Jatta1001, Borrelioosiyhdistys, Bb
LÄÄKETEOLLISUUDEN KEINOJA KASVATTAA LÄÄKKEIDEN KULUTUSTA
Viimeksi muokannut Bb, Ke Helmi 18, 2009 12:14. Yhteensä muokattu 1 kertaa.
Lähettäjä: Soijuv Lähetetty: 31.7.2007 10:51
Seuraavissa artikkeleissa kerrotaan lääketeollisuuden menetelmistä kasvattaa myyntiään esim. tarjoamalla erilaisia etuja lääkäreille, kuten matkoja, aterioita jne. Amerikassa vain viidessä osavaltiossa lääkefirmojen on ilmoitettava antamansa lahjoitukset lääkäreille.
Entisen lääke-esittelijän S. Aharin mukaan hänen tehtävänään oli "selvittää mikä oli lääkärin hinta". Joillekin se oli hieno illallinen kalliissa ravintolassa, joillekin riitti riittävän vakuuttava näyttö lääkkeen tehokkuudesta, joillekin riitti heidän saamansa huomio jne. - perusperiaate on, että kaikki ovat ostettavissa ja vaihtokauppaa käydään. Lääketeollisuus tarjoaa lääkäreille erilaisia lahjoja, ei vain mukeja ja kyniä joissa on lääkefirman nimi. Lääketeollisuus listaa lääkärit sen mukaan, mitä lääkkeitä ja missä määrin he reseptejä kirjoittavat. Eniten reseptejä kirjoittavat saavat parhaat lahjat.
... Lääkefirmat keräävät myös tietoa lääkäreistä, esim. heidän syntymäpäivänsä, harrastuksensa jne."
Originally published July 30 2007
Secret drug company payments to doctors remain legal in 48 states
by David Gutierrez
(NewsTarget) Only five states and the District of Columbia require that pharmaceutical companies report gifts they make to doctors, and even in these jurisdictions the laws are so poorly enforced that the details of these transactions remain a de facto secret, according to a study published in the Journal of the American Medical Association.
Researchers examined public records from Vermont and Minnesota, the only two states that require disclosure by pharmaceutical companies and make that data available to the public. By studying the data from 2002 to 2004, the researchers hoped to gain a better understanding of how money moves from the pharmaceutical to the medical industry.
"What we really found was laws aren't working," said study author Joseph Ross, of the geriatrics department of Mount Sinai School of Medicine in New York.
The researchers found that while reported payments were quite high, the details of those transactions were not available. In other cases, reported payments were so low as to be suspicious. For example, GlaxoSmithKline claimed zero dollars spent in Vermont in the time period studied, yet the state attorney general listed the company as making more payments than any other. In Minnesota, Amgen recorded zero dollars in payments in 2002 or 2004, but more than $4 million in 2003.
Part of the reason for this inconsistency is that gifts of drugs or items not yet on the market can be classified as "trade secrets" and not reported. But Ross believes that this loophole is being exploited.
"To designate every payment made as a trade secret ... seems improbable," he said.
Pharmaceutical companies have been known to give doctors extravagant gifts including all-expense-paid vacations or gourmet dinners as part of their marketing campaigns. According to Dr. Harlan Krumholz, an associate professor at the Yale University School of Medicine, this presents a conflict of interest that the public should know about.
Ross agrees. "If both parties think this payment is appropriate, then this information should be made available to the public," he said. http://www.newstarget.com/021955.html
-----------------------------------------
Originally published July 30 2007
Drug reps use psychological tactics to successfully influence doctors' prescribing habits
by Mike Adams
Pharmaceutical companies spend more than $15 billion each year promoting prescription drugs in the United States. One-third of that amount is spent on "detailing" -- an industry term for drug company representatives' one-on-one promotion to doctors. A paper published April 24, 2007 in the Public Library of Science journal Medicine uncovers the tactics which pharmaceutical sales representatives, commonly called "drug reps," are trained to use in promoting drugs to prescribing physicians.
"It's my job to figure out what a physician's price is. For some it's dinner at the finest restaurants, for others it's enough convincing data to let them prescribe confidently and for others it's my attention and friendship... but at the most basic level, everything is for sale and everything is an exchange," stated former Eli Lilly drug rep Shahram Ahari.
Ahari, no longer a drug rep, co-wrote the paper with Adriane Fugh-Berman, associate professor of physiology and biophysics at Georgetown University Medical Center in Washington, D.C. The paper is based on conversations between Ahari and Fugh-Berman, who researches pharmaceutical marketing.
The writers report that drug reps are trained to gather as much personal information as possible about the doctors to whom they are promoting pharmaceuticals -- from birthdays and hobbies to religious affiliation. Drug reps are trained to note any detail that can be used to establish a personal relationship with a doctor. Ahari stated, "During training, I was told, when you're out to dinner with a doctor, 'The physician is eating with a friend. You are eating with a client.'"
Drug reps offer gifts, and not just mugs and pens inscribed with drug names. "The highest prescribers receive better presents," wrote Ahari. Pharmaceutical companies rank doctors according to the number of prescriptions they write -- from 1 at the low end to 10 for high prescribers. According to Ahari, "Some reps said their 10s might receive unrestricted 'educational' grants so loosely restricted that they were the equivalent of a cash gift."
The source of the 1-to-10 ranking data is prescription tracking. So-called "health information organizations" (including IMS Health, Dendrite and Verispan) purchase prescription records from pharmacies. According to the authors, IMS Health buys records of about 70 percent of prescriptions filled by community pharmacies. Pharmaceutical companies purchase the records and use them to identify high-prescribing doctors.
How the AMA earns millions by helping drug companies buy influence
Prescription tracking records do not always identify doctors by name; in some cases they are identified by a state or federal license number or a pharmacy-specific identifier. To establish the identity of the prescribing doctors, pharmaceutical companies rely on the American Medical Association (AMA), which maintains a Physician Masterfile on every U.S. physician. Citing the New England Journal of Medicine, the authors wrote, "In 2005, database product sales, including an unknown amount from licensing Masterfile information, provided more than $44 million to the AMA."
Once the high prescribers are identified, the drugs reps are then directed to reward those doctors with attention and gifts. The highest prescribing doctors are the ones with whom the drug reps work hardest to build relationships. According to Ahari, "The highest prescribers (9s and 10s) are every rep's sugar mommies and daddies." Lower prescribing doctors are hardly ignored, however; Ahari explained that he was taught to "pick a handful out and make them feel special enough" and then associate increased prescribing with personal attention and a reward such as dinner at a fine restaurant.
When doctors express skepticism about a certain drug, reps will take one of several approaches. One tactic is to present the doctors with journal articles that counter the doctor's perceptions. "Armed with the articles and having hopefully scheduled a 20 minute appointment (so the doc can't escape), I play dumb and have the doc explain to me the significance of my article," wrote Ahari. The drug rep then asks the doctor to prescribe the medication based on his or her own explanation (to the sales rep) of the journal articles.
Yet another tactic, reserved for doctors who prefer a competing drug, is described by Ahari: "We force the doctors to constantly explain their prescribing rationale, which is tiresome. Our intent is to engage in discourse but also to wear down the doc until he or she simply agrees to try the product for specific instances."
The pharmaceutical industry employs 100,000 drug reps whose job is, first and foremost, to sell drugs. Their tactics are on par with some of the most clever and potent brainwashing techniques used throughout the world, including those used on political prisoners to convince them to denounce their home nations. Doctors are, in effect, being successfully targeted and influenced through advanced brainwashing campaigns designed to alter prescribing behavior and sell more high-profit drugs. Far from being immune to such techniques, it appears that physicians are remarkably susceptible to them. http://www.newstarget.com/z021956.html
Seuraavissa artikkeleissa kerrotaan lääketeollisuuden menetelmistä kasvattaa myyntiään esim. tarjoamalla erilaisia etuja lääkäreille, kuten matkoja, aterioita jne. Amerikassa vain viidessä osavaltiossa lääkefirmojen on ilmoitettava antamansa lahjoitukset lääkäreille.
Entisen lääke-esittelijän S. Aharin mukaan hänen tehtävänään oli "selvittää mikä oli lääkärin hinta". Joillekin se oli hieno illallinen kalliissa ravintolassa, joillekin riitti riittävän vakuuttava näyttö lääkkeen tehokkuudesta, joillekin riitti heidän saamansa huomio jne. - perusperiaate on, että kaikki ovat ostettavissa ja vaihtokauppaa käydään. Lääketeollisuus tarjoaa lääkäreille erilaisia lahjoja, ei vain mukeja ja kyniä joissa on lääkefirman nimi. Lääketeollisuus listaa lääkärit sen mukaan, mitä lääkkeitä ja missä määrin he reseptejä kirjoittavat. Eniten reseptejä kirjoittavat saavat parhaat lahjat.
... Lääkefirmat keräävät myös tietoa lääkäreistä, esim. heidän syntymäpäivänsä, harrastuksensa jne."
Originally published July 30 2007
Secret drug company payments to doctors remain legal in 48 states
by David Gutierrez
(NewsTarget) Only five states and the District of Columbia require that pharmaceutical companies report gifts they make to doctors, and even in these jurisdictions the laws are so poorly enforced that the details of these transactions remain a de facto secret, according to a study published in the Journal of the American Medical Association.
Researchers examined public records from Vermont and Minnesota, the only two states that require disclosure by pharmaceutical companies and make that data available to the public. By studying the data from 2002 to 2004, the researchers hoped to gain a better understanding of how money moves from the pharmaceutical to the medical industry.
"What we really found was laws aren't working," said study author Joseph Ross, of the geriatrics department of Mount Sinai School of Medicine in New York.
The researchers found that while reported payments were quite high, the details of those transactions were not available. In other cases, reported payments were so low as to be suspicious. For example, GlaxoSmithKline claimed zero dollars spent in Vermont in the time period studied, yet the state attorney general listed the company as making more payments than any other. In Minnesota, Amgen recorded zero dollars in payments in 2002 or 2004, but more than $4 million in 2003.
Part of the reason for this inconsistency is that gifts of drugs or items not yet on the market can be classified as "trade secrets" and not reported. But Ross believes that this loophole is being exploited.
"To designate every payment made as a trade secret ... seems improbable," he said.
Pharmaceutical companies have been known to give doctors extravagant gifts including all-expense-paid vacations or gourmet dinners as part of their marketing campaigns. According to Dr. Harlan Krumholz, an associate professor at the Yale University School of Medicine, this presents a conflict of interest that the public should know about.
Ross agrees. "If both parties think this payment is appropriate, then this information should be made available to the public," he said. http://www.newstarget.com/021955.html
-----------------------------------------
Originally published July 30 2007
Drug reps use psychological tactics to successfully influence doctors' prescribing habits
by Mike Adams
Pharmaceutical companies spend more than $15 billion each year promoting prescription drugs in the United States. One-third of that amount is spent on "detailing" -- an industry term for drug company representatives' one-on-one promotion to doctors. A paper published April 24, 2007 in the Public Library of Science journal Medicine uncovers the tactics which pharmaceutical sales representatives, commonly called "drug reps," are trained to use in promoting drugs to prescribing physicians.
"It's my job to figure out what a physician's price is. For some it's dinner at the finest restaurants, for others it's enough convincing data to let them prescribe confidently and for others it's my attention and friendship... but at the most basic level, everything is for sale and everything is an exchange," stated former Eli Lilly drug rep Shahram Ahari.
Ahari, no longer a drug rep, co-wrote the paper with Adriane Fugh-Berman, associate professor of physiology and biophysics at Georgetown University Medical Center in Washington, D.C. The paper is based on conversations between Ahari and Fugh-Berman, who researches pharmaceutical marketing.
The writers report that drug reps are trained to gather as much personal information as possible about the doctors to whom they are promoting pharmaceuticals -- from birthdays and hobbies to religious affiliation. Drug reps are trained to note any detail that can be used to establish a personal relationship with a doctor. Ahari stated, "During training, I was told, when you're out to dinner with a doctor, 'The physician is eating with a friend. You are eating with a client.'"
Drug reps offer gifts, and not just mugs and pens inscribed with drug names. "The highest prescribers receive better presents," wrote Ahari. Pharmaceutical companies rank doctors according to the number of prescriptions they write -- from 1 at the low end to 10 for high prescribers. According to Ahari, "Some reps said their 10s might receive unrestricted 'educational' grants so loosely restricted that they were the equivalent of a cash gift."
The source of the 1-to-10 ranking data is prescription tracking. So-called "health information organizations" (including IMS Health, Dendrite and Verispan) purchase prescription records from pharmacies. According to the authors, IMS Health buys records of about 70 percent of prescriptions filled by community pharmacies. Pharmaceutical companies purchase the records and use them to identify high-prescribing doctors.
How the AMA earns millions by helping drug companies buy influence
Prescription tracking records do not always identify doctors by name; in some cases they are identified by a state or federal license number or a pharmacy-specific identifier. To establish the identity of the prescribing doctors, pharmaceutical companies rely on the American Medical Association (AMA), which maintains a Physician Masterfile on every U.S. physician. Citing the New England Journal of Medicine, the authors wrote, "In 2005, database product sales, including an unknown amount from licensing Masterfile information, provided more than $44 million to the AMA."
Once the high prescribers are identified, the drugs reps are then directed to reward those doctors with attention and gifts. The highest prescribing doctors are the ones with whom the drug reps work hardest to build relationships. According to Ahari, "The highest prescribers (9s and 10s) are every rep's sugar mommies and daddies." Lower prescribing doctors are hardly ignored, however; Ahari explained that he was taught to "pick a handful out and make them feel special enough" and then associate increased prescribing with personal attention and a reward such as dinner at a fine restaurant.
When doctors express skepticism about a certain drug, reps will take one of several approaches. One tactic is to present the doctors with journal articles that counter the doctor's perceptions. "Armed with the articles and having hopefully scheduled a 20 minute appointment (so the doc can't escape), I play dumb and have the doc explain to me the significance of my article," wrote Ahari. The drug rep then asks the doctor to prescribe the medication based on his or her own explanation (to the sales rep) of the journal articles.
Yet another tactic, reserved for doctors who prefer a competing drug, is described by Ahari: "We force the doctors to constantly explain their prescribing rationale, which is tiresome. Our intent is to engage in discourse but also to wear down the doc until he or she simply agrees to try the product for specific instances."
The pharmaceutical industry employs 100,000 drug reps whose job is, first and foremost, to sell drugs. Their tactics are on par with some of the most clever and potent brainwashing techniques used throughout the world, including those used on political prisoners to convince them to denounce their home nations. Doctors are, in effect, being successfully targeted and influenced through advanced brainwashing campaigns designed to alter prescribing behavior and sell more high-profit drugs. Far from being immune to such techniques, it appears that physicians are remarkably susceptible to them. http://www.newstarget.com/z021956.html